Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Ions - What They Never Told You

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.

Benzinga

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released topline results on Monday from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive, and often fatal neurological condition.

Benzinga

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

On Tuesday, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Ionis Pharmaceuticals Inc.’s (NASDAQ:IONS) ION582 for Angelman syndrome (AS), a rare neurological disorder.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).

Benzinga

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Benzinga

IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) closed regular trading at $42.81, up 0.78% for the day, before gaining an additional 2.38% in premarket trading to $43.83, according to Benzinga Pro data, following disclosure of insider trading activity by its chief scientific officer.

Benzinga

Why Morgan Stanley Upgraded This Biotech Stock to a Buy

Ionis is shaping up to be one of the most compelling long-term growth stories in biotech today.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) reported second-quarter adjusted earnings of 85 cents on Wednesday. The company reported an adjusted loss of $35 million a year ago.

Benzinga

Navy’s IFC-IOR played key role in the backend in tackling vessel hijacking episode

The Indian Navy’s Information Fusion Centre for Indian Ocean Region (IFC-IOR) located in Gurugram played a quiet but crucial role in the backend as the hijacking incident of (Merchant Vessel) m.v. Ruen unfolded by coordinating between the Navy and with the ship owner. The centre, which marked its 5th anniversary…

The Hindu

S&P Futures Tick Higher as Investors Brace for U.S. Inflation Data, Disney Earnings on Tap

September S&P 500 futures (ESU23) are trending up +0.27% this morning as market participants exercised caution and refrained from big positions in anticipation of Thursday’s U.S. inflation report.

Barchart

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.

Benzinga

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Benzinga

Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol

Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have

Benzinga

Expert Ratings For Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

Indian Ocean Naval Symposium holds maiden maritime exercise

A stepping stone to respond collectively to natural disasters in the region, says official

Benzinga

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have

Benzinga

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced the publication of Phase 2 data for donidalorsen in the New England Journal of Medicine (NEJM). Donidalorsen is an investigational antisense medicine under development for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling. In the Phase 2 study, donidalorsen demonstrated a 90% reduction in…

Benzinga

BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

New England Journal of Medicine

31 stories

NEJM

20 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.